Joint British recommendations on prevention of coronary heart disease in clinical practice

Heart

Volumn 80, Issue SUPPL. 2, 1998, Pages

  Wood, David ^a   Durrington, Paul ^b   McInnes, Gordon ^b   Poulter, Neil ^b   Rees, Alan ^b   Wray, Richard ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; SULFINPYRAZONE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; TRANSLUMINAL CORONARY ANGIOPLASTY; WEIGHT REDUCTION;

ADULT; AGED; CORONARY DISEASE; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PATIENT SELECTION; PHYSICAL EXAMINATION; PRIMARY HEALTH CARE; PROGNOSIS; RISK FACTORS; SOFTWARE; THERAPY, COMPUTER-ASSISTED;

EID: 0032437504     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (212)

1. Wood DA, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1998;19:1434-503.
2. British Cardiac Society working group on coronary prevention. Conclusions and recommendations. Br Heart J 1987; 57:188-9.
3. Shepherd J, Betteridge DJ, Durrington PN, et al. British Hyperlipidaemia Association guidelines on strategies for reduction of coronary heart disease and desirable limits for blood lipid levels. BMJ 1987;295:1245-6.
4. Betteridge DJ, Dodson PM, Durrington PN, et al. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993;69:359-69.
5. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993;306: 983-7.
6. Department of Health. The health of the nation: a strategy for health in England. London: HMSO, 1992.
7. Aspire Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (action on secondary prevention through intervention to reduce events). Principal results. Heart 1996;75:334-42.
8. Anderson KM, Wilson PWF, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. Circulation 1991;83:356-62.
9. Standing Medical Advisory Committee on use of statins. NHS Executive. London: Department of Health, May 1997.
10. Dyslipidaemia Advisory Group, on behalf of the scientific committee of the National Heart Foundation of New Zealand. 1996 National Heart Foundation guidelines for the assessment and management of dyslipidaemia. NZ Med J 1996;109:224-32.
11. Haq IU, Jackson PR, Yeo WW, et al. A comparison of methods for targeting CHD risk for primary prevention [abstract]. Heart 1997;77(suppl 1):P36.
12. Assmann G, Culler P, Schulte H. The Munster heart study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998;19(suppl A):A2-11.
13. Schulte H, Assmann G. CHD risk equations, obtained from the Framingham heart study, applied to the PROCAM study of cardiovascular risk factors. 1991;1:126-33.
14. Haq IU, Ramsay LE, Pickin JN, et al. Lipid lowering for prevention of coronary heart disease: what policy now? Clin Sci 1996;91:399-413.
15. West of Scotland Coronary Prevention (WOSCOP) Group. West of Scotland coronary prevention study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996;348:1339-42.
16. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-23.
17. Mann JI, Crooke M, Fear H, et al. Guidelines for detection and management of dyslipidaemia. NZ Med J 1993;106: 133-42.
18. MacMahone S, Peto R, Cutter J, et al. Blood pressure, stroke and coronary heart disease. Part 1: Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335: 765-74.
19. Law MR, Wald NJ, Wu T, et al. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994;308:363-6.
20. Sackett DL, Anderson GD, Milner R, et al. Concordance for coronary risk factors among spouses. Circulation 1975;52: 589-95.
21. Garrison RJ, Castelli WP, Feinleib M, et al. The association of total cholesterol, triglycerides and plasma lipoprotein cholesterol levels in first degree relatives and spouse pairs. Am J Epidemiol 1979;110:313-21.
22. Pyke SDM, Wood DA, Kinmonth AL, et al and on behalf of the BFHS group. Changes in coronary risk and risk factor levels in couples following lifestyle intervention: the British family heart study. Arch Fam Med 1997;6:3254-360.
23. Daly LE, Mulcahy R, Graham IM, et al. Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. BMJ 1983;287:324-26.
24. Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 1995;155:1933-41.
25. Da Costa A, Guy JM, Tardly B. Myocardial infarction and nicotine patch: a contributing factor? Eur Heart J 1993;14: 1709-11.
26. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335: 1792-8.
27. Burr ML, Gilbert JF, Holliday RM, et al. Effects of changes in fat, fish and fibre intakes on death and myocardial infarction; diet and reinfarction trial (DART). Lancet 1989;ii:757-61.
28. Lorgeril M, Renaud S, Mamalle N, et al. Mediterranean alpha-linoleic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454-9.
29. Mancini GBJ. Angiographic trials of lipid lowering therapy: an update. Curr Opin Lipidol 1995;6:379-85.
30. Hjermann I, Velve Byre K, Holme I, et al. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo study group of a randomised trial in healthy men. Lancet 1981;ii:1304-10.
31. Manson JE, Gaziano JM, Jonas MA, et al. Antioxidants and cardiovascular disease: a review. J Am Coll Nutr 1993;12: 426-32.
32. Department of Health. Diet and risk. Report of the Committee on Medical Aspects of Food Policy (COMA). London: HMSO, 1994.
33. Cutler JA, Follmann D, Elliot P, et al. An overview of randomised trials of sodium reduction and blood pressure. Hypertension 1991;17(suppl 1):127-33.
34. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I: Analysis of observational data among populations. BMJ 1991;302:811-5.
35. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? III: Analysis of data from trials of salt reduction. BMJ 1991;302.819-24.
36. Swales JD. Dietary salt and blood pressure: The role of meta-analysis. J Hypertens 1990;9(suppl 6):42-6.
37. Stamler R, Grimm R, Gisch FC, et al. Control of high blood pressure by nutritional therapy. Final report of a four year randomised controlled trial: the Hypertension control program. JAMA 1987;247:1484-91.
38. Swales JD. Non-pharmacological antihypertensive therapy. Eur Heart J 1988;9(suppl G):45-52.
39. Margetts BM, Beilin LJ, Vandongen R, et al. Vegetarian diet in mild hypertension: a randomised controlled trial. BMJ 1986;293:1468-71.
40. Rouse IL, Beilin LJ, Armstrong BK, et al. Blood pressure lowering effect of a vegetarian diet: controlled trial in normotensive subjects. Lancet 1983;i:5-10.
41. Smith SJ, Markandu WD, Sagnella FA, et al. Moderate potassium chloride supplementation in essential hypertension: is it additive to moderate sodium restriction? BMJ 1985;291:110-13.
42. Jackson R, Beaglehole R. The relationship between alcohol and coronary heart disease: is there a protective effect? Curr Opin Lipidol 1993;4:21-6.
43. Klatsky AL, Friedman GD, Siegelaub AB, et al. Alcohol consumption and blood pressure. Kaiser - Permanent and multiphasic health examination data. N Engl J Med 1977;296:1194-2000.
44. Marmot MG, Elliott P, Shipley MJ, et al. Alcohol and blood pressure: the INTERSALT study. BMJ 1994;308:1263-7.
45. Oldridge NB, Guyart GH, Fischer ME, et al. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA 1988;260:945-50.
46. O'Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80:234-44.
47. Coats A, Mc Gee H, Stokes H, et al, eds. British Association of Cardiac Rehabilitation. Guidelines for cardiac rehabilitation. Oxford: Blackwell Science, 1995.
48. Horgan J, Bethell H, Carson P, et al. Working party report on cardiac rehabilitation. Br Heart J 1992;67:412-8.
49. Task force of the working group on cardiac rehabilitation of the European Society of Cardiology. Long-term comprehensive care of cardiac patients. Eur Heart J 1992;13(suppl C):1-45.
50. Browner WS, Hulley SB. Effect of risk factor status on treatment criteria. Implications of hypertension trials. Hypertension 1989;13(suppl I):51-6.
51. Kannel WB. Hypertension and the risk of cardiovascular disease. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press, 1990:101-17.
52. Office of Population Censuses and Surveys, Social Survey Division. Health Survey for England 1993. London: HMSO, 1995.
53. Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1983;371:335-71.
54. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish verapamil infarction trial II-DAVIT II). Am J Cardiol 1990;66:779-84.
55. The Danish Study Group in Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart 1984;5:516-28.
56. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q wave myocardial infarction: results of a double-blind randomized multicenter trial. N Engl J Med 1986;315:423-9.
57. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319: 385-92.
58. Jespersen CM, Hansen JF and the Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on reinfarction and cardiovascular events in patients with arterial hypertension included in the Danish verapamil infarction trial II. J Hum Hypertens 1994;8:85-8.
59. Moss AJ, Oakes D, Rubison M, et al. Effects of diltiazem on long-term outcome after acute myocardial infarction in patients with and without a history of systemic hypertension. Am J Cardiol 1991;68:429-33.
60. Pfeffer MA, Braunwald E, Moye LA, et al, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327: 669-77.
61. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:812-28.
62. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987;i:581-4.
63. D'Agostini RB, Belanger AJ, Kannel WB, et al. Relationship of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham study. BMJ 1991;303:385-9.
64. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991;338: 1281-5.
65. Medical Research Council Working Party. Medical Research Council trial on treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.
66. Systolic Hypertension in Elderly Patients (SHEP) Cooperative Research Group. Prevention of stroke by antihypertensive treatment in older persons with isolated systolic hypertension. JAMA 1991;265:3255-64.
67. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without pre-existing cardiovascular disease. N Engl J Med 1990;322:1700-7.
68. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-73.
69. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994;308:373-9.
70. Ericsson G-G, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53.
71. Multicentre Anti-Atheroma Study Investigators. Effect of simvastatin on coronary atheroma: the multicentre antiatheroma study (MAAS). Lancet 1994;344:633-8.
72. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study. Lancet 1994;344:1383-9.
73. Pedersen TR, Kjeksus J, Berg K, et al. Baseline serum cholesterol and treatment effect in the Scandinavian simvastatin survival study (4S). Lancet 1995;345:1274-5.
74. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-9.
75. Shepherd J, Cobbe SM, Ford I, et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301-7.
76. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
77. Mbewu AD, Durrington PN, Bulleid S, et al. The immediate effect of streptokinase on serum lipoprotein (a) concentration and the effect of myocardial infarction on serum lipoprotein (a), apolipoprotein A1 and B, lipids and C-reactive protein. Atherosclerosis 1993;103:65-71.
78. Shaukat N, Ashraf SS, Mackness MI, et al. A prospective study of serum lipoproteins after coronary bypass surgery. Quart J Med 1994;87:539-45.
79. Thompson GR. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis 1997;131:1-5.
80. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995;91:2274-82.
81. Frick MH, Elo O, Heinonen O, et al. Hensinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
82. Modan B, Assmann G, Bauer P, et al. Statement of the international review and advisory board of the bezafibrate infarction prevention study after its meeting on May 31, 1995, in Charlottesville, Virginia. Circulation 1995;92: 1675.
83. Feher MD, Foxton J, Banks D, et al. Long-term safety of statin fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. Br Heart J 1995;74:14-17.
84. Smith JWA, Jansen GH, de Bruin TWA, et al. Treatment of combined hyperlipidaemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. J Cardiol 1995;76:126-8A.
85. Farrer M, Fulcher G, Albers CJ, et al. Patients undergoing coronary artery bypass surgery are at a high risk of impaired glucose tolerance and diabetes mellitus during the first postoperative year. Metabolism 1995;44:1016-27.
86. Pyörälä K, Pedersen TJ, Kjerkshus J, et al and the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997;20:614-20.
87. Dean JD, Durrington PN. Treatment of dyslipoproteinaemia in diabetes mellitus. Diabet Med 1996;13:297-312.
88. Durrington PN. Statins and fibrates in the management of diabetic dylipidaemia. Diabetes Medicine 1997;14:513-16.
89. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes management on macrovascular event and risk factors in the diabetes control and complications trial (DCCT). Am J Cardiol 1995;75:894-903.
90. Malberg K, Ryder L, Efendic S, et al. Randomised trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.
91. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996;347:947-50.
92. Antiplatelets Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
93. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
94. The Study of Left Ventricular Dysfunction (SOLVD) Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
95. The Study of Left Ventricular Dysfunction (SOLVD) Investigators. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
96. Cohn JN, Johnson G, Zlesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325: 303-10.
97. Fonarow GC, Chatimsky-Fallick C, Warnes Stevenson L, et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibiton with captopril on mortality in advanced heart failure, the Hy-C trial. J Am Coll Cardiol 1992;19:842-50.
98. Gruppo Italiano per lo Studio delia Sopravvivneza nell'infarto Miocardico. GISSI-3 effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
99. Fourth International Study of Infant Survival (ISIS-4) Collaborative Group. A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in over 58050 patients with suspected acute myocardial infarction. Lancet 1995;345:66-85.
100. Smith P, Arneson H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-52.
101. Blankenhorn DH, Nessim SA, Johnson RI, et al. Beneficial effects of combined cholestipol-niacin therapy on coronary atherosclerosis and coronary venous hypass grafts. JAMA 1987;257:3233-40.
102. Post Coronary Artery Bypass Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts. N Engl J Med 1997;336:153-62.
103. Carter AB. Hypertensive therapy in stroke survivors. Lancet 1970;i:485-9.
104. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment in stroke recurrence. JAMA 1974;229:409-18.
105. Gersh BJ, Rihal CS, Rooke TW, et al. Evaluation and management of patients with both peripheral vascular and coronary artery disease. J Am Coll Cardiol 1991;18:203-14.
106. Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney. N Engl J Med 1983;308:377-86.
107. Wenting G, Derkx F, Tna Tjiong L, et al. Risks of angiotensin converting enzyme inhibition in renal artery stenosis. Kidney Int 1987;31 (suppl 20):S180-3.
108. Hypertension Detection and Follow-Up Program Cooperative Group. Five year findings of the hypertension detection and follow-up program. 1. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;252:2562-71.
109. Davey-Smith G, Song F, Sheldon T. Cholesterol lowering and mortality, the importance of considering initial level of risk. BMJ 1993;306:1367-73.
110. Austoker J, Sanders D, Fowler G. Smoking and cancer: smoking cessation. BMJ 1994;308:1478-82.
111. Dobson AJ, Alexander HM, Heller RF, et al. How soon after quitting smoking does risk of heart attack decline? J Clin Epidemiol 1991;44:1247-53.
112. Rosenberg L, Kaufman DW, Helmrich SP, et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985;313:1512-4.
113. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990;322:213-7.
114. Watkins LO, Neaton JD, Kuller LH. Social differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the usual care group of the multiple risk factor intervention trial (MRFIT). Am J Cardiol 1986; 57:538-45.
115. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle aged women. Arch Intern Med 1994;154: 169-75.
116. Allied Dunbar, Sports Council and Health Education Authority. Allied Dunbar national fitness survey. England: Belmont Press, 1992.
117. Blair SN, Kohl HW, Paffenbarger RS, et al. Physical fitness and all cause mortality. A prospective study of healthy men and women. JAMA 1989;262:2395-401.
118. Paffenberger RS, Hyde RT, Wing AI, et al. The association of changes in physical activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328:538-45.
119. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990;132:612-28.
120. Lakka TA, Vaäläinen JM, Raurama R, et al. Relation of leisure time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction in men. N Engl J Med 1994;330:1549-54.
121. Morris JN, Clayton DG, Everitt MG, et al. Exercise in leisure time: coronary attack and death rates. Br Heart J 1990;63:325-34.
122. Neil HAW, Roe L, Godlee RJP, et al. Randomised trial of lipid lowering dietary advice in general practice: the effects on lipids, lipoproteins and antioxidants. BMJ 1995;310: 569-73.
123. Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. BMJ 1991;303:953-7.
124. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994;50:272-98.
125. Australian Therapeutic Trial in Mild Hypertension Management Committee. The Australian therapeutic trial in mild hypertension. Lancet 1980;i:1261-7.
126. Linjer E, Hansson L. Underestimation of the true benefits of antihypertensive treatment: an assessment of some important sources of error. J Hypertens 1997;15:221-5.
127. Zanchetti A. Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage. Blood Pressure 1992;1:205-11.
128. MacMahon S, Peto R, Cutler J, et al. Blood pressure stroke and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335: 765-74.
129. Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension: the Framingham study. Circulation 1986;61:1179-82.
130. Medical Research Council Working Party on Mild to Moderate Hypertension. The MRC mild hypertension trial; some subgroup results. In: Strasser T, Ganten D, eds. Mild hypertension: from drug trials to practice. New York: Raven Press, 1987:9-20.
131. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-64.
132. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97-104.
133. Jackson R, Barkham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993;307:107-10.
134. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1989;13(suppl 1):2-12.
135. Hypertension Detection and Follow-Up Program Cooperative Research Group. Mortality findings for stepped-care and referred care participants in the hypertension detection and follow-up program stratified for other risk factors. Prev Med 1985;14:312-35.
136. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. Arch Intern Med 1993;153: 154-83.
137. Myers MG, Carruthers SG, Leenan FHH, et al. Recommendations from the Canadian Hypertension Society consensus conference on the pharmacological treatment of hypertension. Can Med Assoc J 1989;140: 1141-9.
138. World Health Organization/International Society of Hypertension Guidelines Subcommittee. 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. J Hypertens 1993;11:905-18.
139. Amery A, Birkenghager W, Brisko P, et al. Mortality and morbidity results from the European working party on high blood pressure in the elderly trial. Lancet 1985;i:1349-54.
140. Report by the Management Committee. Australian therapeutic trial in mild hypertension: untreated mild hypertension. Lancet 1982;i:185-91.
141. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1995;328: 914-21.
142. Treatment of Mild Hypertension Research Group. The treatment of mild hypertension study: a randomized, placebo-controlled trial of a nutritional hygienic regimen along with various drug monotherapies. Arch Intern Med 1991;151:1413-23.
143. Carlsen JE, Kober L, Torp-Pedersen C, et al. Relation between dose of bendrofluazide, antihypertensive effect and adverse biochemical effects. BMJ 1990;300:975-8.
144. Rosman J, Weidmann P, Ferrari P. Antihypertensive drugs and serum lipoproteins. Drug Development 1990;3(suppl 1):129-39.
145. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med 1984;3:409-20.
146. Sever PS, MacKay JA. The hypertension trials. J Hypertens 1996;14(suppl 2):529-34.
147. Ménard J, Day M, Chatellier G. Individualised drug therapy: is it time for a change from mass strategy? In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and management, 2nd edn. New York: Raven Press, 1995:1035-45.
148. Swales JD, Ramsay LE, Coope JR, et al. Treating mild hypertension. Report of the British Hypertension Society working party. BMJ 1989;298;694-8.
149. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
150. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998;16:747-53.
151. Holme I. An analysis of randomised controlled trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990;82:1916-24.
152. Smith GD, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992;304;431-4.
153. Committee of Principal Investigators. Report on a cooperative trial on primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-118.
154. Heady JA, Morris JN, Oliver MF. WHO clofibrate/ cholesterol trial: clarifications. Lancet 1992;340:1405-6.
155. Downs GR, Clearfield M, Weiss S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS. Air Force/Texas coronary atherosclerosis study. JAMA 1998;279:1615-22.
156. Durrington PN. Hyperlipidaemia. Diagnosis and management, 2nd edn. London: Butterworth-Heinemann, 1995.
157. Goldstein JL, Brown MS. Familial hypercholesterolaemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzymne A reductase activity associated with over production of cholesterol. Proc Natl Acad Sci USA 1973;70:2804-8.
158. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality is treated heterozygous familial hypercholesterolaemia: implication for clinical management. Atherosclerosis [In press.]
159. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolaemia with combined drug regimes. JAMA 1990; 264:3007-12.
160. Wray R, Neil A, Rees A. Hyperlipidaemia in childhood: a screening strategy. UK recommendations. In: Neil A, Rees A, Taylor C, eds. Hyperlipidaemia in childhood. London: Royal College of Physicians, 1996:99-105.
161. Pyörälä K, Laakso M, Unsitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:4630-524.
162. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
163. Krolewski AS, Warran JH, Valsania P, et al. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1990;90(suppl 2A):565-615.
164. Fuller JH, Shipley MJ, Rose G, et al. Coronary heart disease risk and impaired glucose tolerance: the Whitehall study. Lancet 1980;i:1373-6.
165. Haftner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8.
166. Barrett-Connor E, Wingard D, Criqui MH, et al. Is borderline fasting hyperglycaemia a risk factor for cardiovascular death? J Chron Dis 1984;37:773-9.
167. Alberti KGMM, Zimmet P, for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and clarification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
168. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-92.
169. Johnston CI, Cooper ME, Nicholls GM. Meeting report of the International Society of Hypertension conference on hypertension and diabetes. J Hypertens 1992;10:393-7.
170. Lewis EJ, Hunsicker LG, Bain RP, et al, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
171. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to micro-albuminuria. Lancet 1995;346:1080-4.
172. Parving HH. Initiation and progression of diabetic nephropathy. N Engl J Med 1996;355:1682-3.
173. Cooper ME. Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 1998;352:213-19.
174. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al, for the Modification of Diet in Renal Disease Study Group. Achievement and safety of a low blood pressure goal in chronic renal disease. Hypertension 1997;29:641-50.
175. The Hypertension in Diabetes Study Group. Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993;11:309-17.
176. The Hypertension in Diabetes Study Group. Hypertension in diabetes study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993;11:319-25.
177. Gall MA, Hougaard P, Borch-Johnsen K, et al. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997;314: 783-8.
178. UK prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
179. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
180. Langford HG. All-cause mortality in the hypertension detection and follow-up program: findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis 1986;29(suppl, pt 3):29-54.
181. Durrington PN. Serum high density lipoprotein cholesterol in diabetes mellitus: an analysis of factors which influence its concentration. Clin Chem Acta 1980;104:11-23.
182. Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki heart study. Diabetes Care 1992;15:820-5.
183. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-41.
184. Degoulet P, Legrain M, Reach I, et al. Mortality risk factors in patients treated by chronic haemodialysis. Nephron 1982;31:103-10.
185. Short CD, Durrington PN. Hyperlipidaemia and renal disease. Bailliere's Clinical Endocrinology and Metabolism 1990; 4:777-806.
186. Bulpitt CJ, Beevers DG, Butter A, et al. The survival of treated hypertensive patients and their cause of death: a report from the Department of Health and Social Security hypertension care computing project (DHCCP). J Hypertens 1986;4:93-9.
187. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazapril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.
188. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997;349:1857-63.
189. Giatras I, Lau J, Levey AS, the Angiotensin-Converting-Enzyme Inhibition
190. Klahr S, Lew AS, Beck GJ, et al, for the Modification on Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-84.
191. Anastos K, Charney P, Charan RA, et al. Hypertension in women: what is really known? Ann Intern Med 1991;115: 287-93.
192. Gueyffier F, Boutitic F, Boissel J-P, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in men and women. A meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med 1997;126:761-7.
193. Crane MG, Harris JJ, Winsor W. Hypertension, oral contraceptive agents, and conjugated estrogens. Ann Intern Med 1971;74:13-21.
194. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997;315:149-53.
195. Mabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069-75.
196. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996;348:498-505.
197. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996;348:505-10.
198. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1997;349: 1202-9.
199. Balarajan R. Ethnicity and variations in mortality from coronary heart disease. Health Trends 1996;28:45-51.
200. McKeigue PM, Miller GJ, Marmot MG. Coronary heart disease in south Asians overseas: a review. J Clin Epidemiol 1989;42:597-609.
201. Shaukat N, Cruickshank JK. Coronary artery disease: impact upon black and ethnic minority people. In: Hopkins A, Bahi V, eds. Access to health care for people from black and white minorities. London: Royal College of Physician, 1993: 133-46.
202. Bhatnagar D, Anand S, Durrington PN, et al. Coronary risk factors in people from Indian subcontinent living in west London and their siblings in India. Lancet 1995;345: 405-9.
203. McKeigue PM, Marmot MG, Syndercombe-Court YD, et al. Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in east London. Br Heart J 1988;60:390-6.
204. Cruickshank JK, Cooper J, Burnett M, et al. Ethnic differences in fasting plasma C-peptide and insulin in relation to glucose tolerance and blood pressure. Lancet 1991;338: 842-7.
205. McKeigue PM, Pierperpoint T, Ferrie JE, et al. Relationship of glucose tolerance and hyperinsulinaemia to body fat pattern in south Asians and Europeans. Diabetologia 1992; 35:785-91.
206. Shelgiker KM, Hockaday TDR, Yajjnik CS. Central rather than generalized obesity is related to hyperglycaemia in Asian Indian subjects. Diabetic Med 1991;8:712-17.
207. Laws A, Jeppesen JL, Maheux PC, et al. Resistance to insulin stimulated glucose uptake and dyslipidaemia in Asian Indians. Arterioscler Thromb 1994;14:917-22.
208. Seevak L, McKeigue PM, Marmot M. Relationship of hyperinsulinaemia to dietary intake in south Asian and European men. Am J Clin Nutr 1994;59:1069-74.
209. Casper M, Wing S, Strogatz D. Variation in the magnitude of black-white differences in stroke mortality by community occupational structure. J Epidemiol Commun Health 1991;45:302-4.
210. Klatsky AL, Armstrong MA, Friedman GD. Racial differences is cerebrovascular disease hospitalizations. Stroke 1991;22:299-304.
211. Petrie JC, O'Brien ET, Littler WA, et al. British Hypertension Society recommendations on blood pressure measurement. BMJ 1986;293:611-15.
212. Pickering TG. Can ambulatory blood pressure monitoring improve the diagnosis of mild hypertension? J Hypertens 1990;8(suppl 6):S43-7.